<DOC>
	<DOCNO>NCT01913600</DOCNO>
	<brief_summary>Prospective , multi-center , non-randomized , single-arm , open-label study ass safety efficacy Resolute Integrity Stent treatment de novo lesion native coronary artery reference vessel diameter ( RVD ) 2.25 mm 4.2 mm patient receive extend length stent ( 34 mm 38 mm ) refer Extended Length Study .</brief_summary>
	<brief_title>Resolute Integrity US Extended Length Sub-Study ( RI-US XL )</brief_title>
	<detailed_description>The purpose postapproval study conduct prospective , multi-center evaluation procedural clinical outcome subject treat commercially available 34 mm 38 mm Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System . Descriptive statistic 95 % confidence interval calculate clinically relevant variable describe separate statistical analysis plan .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>General Angiographic Inclusion Criteria highlight : Acceptable candidate percutaneous coronary intervention ( PCI ) , stenting , emergency coronary artery bypass graft surgery Clinical evidence ischemic heart disease , stable unstable angina , silent ischemia and/or positive functional study Informed consent Patient agree comply specify followup evaluation Single target lesion two target lesion locate separate coronary artery De novo lesion ( ) native coronary artery ( y ) Target lesion ( ) ≤ 35 mm length Target vessel ( ) reference vessel diameter 2.25 mm 4.2 mm General Angiographic Exclusion Criteria highlight : Within 7 day index procedure platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ ; White blood cell ( WBC ) count &lt; 3,000 cells/mm³ ; serum creatinine level &gt; 2.5 mg/dl Acute Myocardial Infarction ( MI ) within 72 hr intend trial procedure ( QWMI elevation Creatine KinaseMB ( CKMB ) &gt; lab upper limit normal ) Previous PCI target vessel ( ) within 9 month prior procedure Planned PCI vessel within 30 day postindex procedure and/or plan PCI target vessel ( ) within 12 month postindex procedure History stroke Transient Ischemic Attack ( TIA ) within prior 6 month Participating investigational drug/device study complete primary endpoint interferes study endpoint Inability comply require trial antiplatelet regimen Previous stent target vessel unless least 9 month since stent place target lesion ( ) is/are least 15 mm previous stent Target vessel ( ) has/have lesion w/ &gt; 40 % diameter stenosis Unprotected leave main coronary artery disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>TARGET LESION REVASCULARIZATION ( TLR )</keyword>
	<keyword>TARGET VESSEL REVASCULARIZATION ( TVR )</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>MYOCARDIAL INFARCTION ( MI )</keyword>
	<keyword>PERCUTANEOUS CORONARY INTERVENTION ( PCI )</keyword>
	<keyword>STENT THROMBOSIS</keyword>
	<keyword>TARGET LESION FAILURE ( TLF )</keyword>
</DOC>